口服高效疾病修正药物在多发性硬化缓解期治疗中的研究进展  

Advances in oral high-efficacy disease-modifying drugs in the treatment of multiple sclerosis in remission

作　　者：刘月月 付蓉 王欣 贾羽 张兰[4] LIU Yue-yue;FU Rong;WANG Xin;JIA Yu;ZHANG Lan(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 211198,China;School of Pharmacy,Hangzhou Medical College,Hangzhou 310053,China;Bristol-Myers Squibb(China)Investment Co.Ltd,Shanghai 200040,China;Department of Pharmacy,National Center Research Center of Geriatric Disease,Xuanwu Hospital,Capital Medical University,Beijing 100053,China)

机构地区：[1]中国药科大学国际医药商学院,南京211198 [2]杭州医学院药学院,杭州310053 [3]百时美施贵宝(中国)投资有限公司,上海200040 [4]首都医科大学宣武医院药学部国家老年疾病临床医学研究中心,北京100053

出　　处：《临床药物治疗杂志》2024年第4期6-10,共5页Clinical Medication Journal

摘　　要：多发性硬化(MS)是一种以中枢神经系统炎性脱髓鞘病变为主要特点的免疫介导性疾病,认知障碍是患者疾病负担的重要成因。减少脑容量丢失和改善认知已成为疾病缓解期治疗目标的重要组成部分,口服高效疾病修正治疗(DMT)药物鞘氨醇-1-磷酸受体调节剂是当前国内常用的MS缓解期DMT方案。本文通过文献回顾,对国内上市的口服高效DMT药物的疗效、不良反应和患者用药监测管理进行现状综述和未来展望。Multiple sclerosis(MS)is an immune-mediated disease characterized by inflammatory demyelinating lesions of the central nervous system.Cognitive impairment is an important contributor to patients'disease burden.Reducing brain volume loss and improving cognition have become important components of the treatment goals of MS in remission and oral high-efficacy disease modifying treatment(DMT)drugs(sphingosine 1 phosphate)are currently commonly used in China as DMT regimens.Through literature review,this article provided an overview of the current status and future outlook of the effi⁃cacy and adverse events of domestically marketed oral high-efficacy DMT drugs,as well as patient medication monitoring and management.

关 键 词：多发性硬化 口服高效疾病修正药物 疗效证据 不良反应 用药管理 

分 类 号：R971[医药卫生—药品]